IRIS
ROTTOLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.024
EU - Europa 15.402
AS - Asia 7.759
SA - Sud America 1.368
Continente sconosciuto - Info sul continente non disponibili 492
AF - Africa 338
OC - Oceania 39
Totale 44.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.650
GB - Regno Unito 3.135
IT - Italia 3.039
CN - Cina 2.790
RU - Federazione Russa 2.618
SG - Singapore 2.159
IE - Irlanda 1.891
BR - Brasile 1.092
UA - Ucraina 1.072
SE - Svezia 951
FR - Francia 931
VN - Vietnam 853
DE - Germania 790
HK - Hong Kong 634
FI - Finlandia 445
KR - Corea 346
IN - India 235
CA - Canada 217
BD - Bangladesh 151
ZA - Sudafrica 136
ES - Italia 111
TR - Turchia 107
AR - Argentina 95
JP - Giappone 90
PL - Polonia 76
MX - Messico 74
NL - Olanda 74
NG - Nigeria 69
IQ - Iraq 64
BE - Belgio 53
CZ - Repubblica Ceca 51
CO - Colombia 46
ID - Indonesia 40
EC - Ecuador 37
PK - Pakistan 35
AU - Australia 34
AT - Austria 32
VE - Venezuela 31
UZ - Uzbekistan 30
CI - Costa d'Avorio 29
MA - Marocco 28
SA - Arabia Saudita 28
JM - Giamaica 23
PH - Filippine 19
IL - Israele 18
KE - Kenya 18
LT - Lituania 18
CL - Cile 17
PY - Paraguay 17
AZ - Azerbaigian 15
IR - Iran 14
PT - Portogallo 14
RO - Romania 14
MY - Malesia 13
TN - Tunisia 13
GR - Grecia 12
JO - Giordania 12
KZ - Kazakistan 12
PE - Perù 12
UY - Uruguay 12
KG - Kirghizistan 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
EG - Egitto 10
EU - Europa 10
DZ - Algeria 9
NP - Nepal 9
BG - Bulgaria 8
CH - Svizzera 8
AL - Albania 7
BO - Bolivia 7
ET - Etiopia 7
HU - Ungheria 7
TT - Trinidad e Tobago 7
EE - Estonia 6
HN - Honduras 6
LU - Lussemburgo 6
NI - Nicaragua 6
XK - ???statistics.table.value.countryCode.XK??? 6
BB - Barbados 5
CY - Cipro 5
DK - Danimarca 5
LB - Libano 5
LV - Lettonia 5
OM - Oman 5
PA - Panama 5
PS - Palestinian Territory 5
DO - Repubblica Dominicana 4
KW - Kuwait 4
LK - Sri Lanka 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
QA - Qatar 4
RS - Serbia 4
SC - Seychelles 4
TH - Thailandia 4
AM - Armenia 3
AO - Angola 3
BY - Bielorussia 3
GE - Georgia 3
Totale 43.880
Salva come PNG Salva come JPEG
Città #
Southend 2.703
Dublin 1.881
Dallas 1.856
Fairfield 1.794
Ashburn 1.359
Singapore 1.238
Chandler 1.143
Houston 903
San Jose 865
Jacksonville 863
Woodbridge 783
Santa Clara 778
Beijing 721
Moscow 710
Seattle 653
Wilmington 603
Hong Kong 597
Milan 567
Cambridge 535
Ann Arbor 468
Council Bluffs 445
Siena 416
Princeton 361
Hefei 334
Seoul 309
Los Angeles 280
The Dalles 280
Nanjing 273
New York 259
Ho Chi Minh City 245
Helsinki 226
Rome 225
Lauterbourg 194
Hanoi 181
Munich 158
Menlo Park 151
Boardman 148
Buffalo 122
Dearborn 120
Johannesburg 119
Nanchang 117
Florence 115
San Diego 110
Dong Ket 95
São Paulo 93
London 87
Shanghai 86
San Mateo 84
Columbus 82
Chicago 78
Tokyo 73
Shenyang 71
Abuja 67
Málaga 67
Chennai 66
Orem 66
Tianjin 60
Warsaw 59
Hebei 54
Changsha 53
Izmir 53
Düsseldorf 52
Frankfurt am Main 50
Turku 50
Ottawa 49
Da Nang 48
Figino 47
Hangzhou 47
Montreal 46
Kunming 45
Washington 43
San Francisco 42
Toronto 42
Guangzhou 41
Redondo Beach 40
Norwalk 39
Rio de Janeiro 39
Brussels 38
Brooklyn 37
Fremont 37
Jiaxing 36
Jinan 35
Catania 34
Denver 34
Phoenix 33
Brno 32
Haiphong 32
Atlanta 31
Nuremberg 31
Bengaluru 30
Boston 30
Gavirate 30
Poplar 30
Amsterdam 29
Abidjan 28
Belo Horizonte 28
Turin 28
Manchester 27
Stockholm 27
Seongnam 26
Totale 28.945
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.069
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 707
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients 452
Cytokine modulators in the treatment of sarcoidosis 407
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 399
null 398
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 370
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 361
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 317
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 312
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 307
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 297
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 294
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 289
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 285
Exhaled nitric oxide in interstitial lung diseases 280
Asbestos exposure assessment by mineralogical analysis of bronchoalveolar lavage fluid 277
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 277
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 276
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 276
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 274
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 273
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 273
A difficult case: sarcoidosis with CNS involvement or sarcoidosis associated with multiple sclerosis? 272
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 269
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 269
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 267
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 267
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 265
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 265
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 263
Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients 259
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 257
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 257
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 257
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 253
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 252
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 251
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 250
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 249
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 247
Serum amyloid A in patients with idiopathic pulmonary fibrosis 247
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 246
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis 244
A functional proteomics approach to the comprehension of sarcoidosis 242
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 241
Chitotriosidase activity in patients with interstitial lung disesaes 239
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 238
Abnormalities in calcium metabolism in sarcoidosis 237
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 237
Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis 236
2D electrophoretic maps of BAL proteins in fibrosing lung diseases 236
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 236
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 235
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease 235
Adaptive immune responses in primary cutaneous sarcoidosis 233
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 230
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 230
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 229
Chitotriosidase: a sensitive biomarker of sarcoidosis 229
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 229
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 228
A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis 227
Bone ultrasonography in glucocorticoid induced osteoporosis 227
The analysis of tryptase in serum of sarcoidosis patients 226
Quality of life, anxiety and depression in Sarcoidosis 226
Proteome analysis of bronchoalveolar lavage in lung diseases 225
Analysis of alveolar and peripheral CD45RO+ T-lymphocytes in sarcoidosis 224
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial 221
Assessment of cardiac involvement in sarcoidosis by echocardiography 220
Phenotypes of organ involvement in sarcoidosis 220
Extracorporeal Photopheresis in Lung Transplantation 218
Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study 217
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors 215
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 215
Sarcoidosis with upper respiratory tract involvement 215
Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement 215
The pharmacological treatment of bronchiectasis 215
Severe acute graft versus host disease after lung transplant: report of a case successfully treated with high dose corticosteroids 215
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 214
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 213
Serum amyloid A: A potential biomarker of lung disorders 213
Serum analysis of coagulation factors in IPF and NSIP 211
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 211
Doubts and certainness in diagnosis of pulmonary embolism in the elderly 209
Effects of calcitriol on IFN-gamma production by alveolar and peripheral lymphocytes of patients with sarcoidosis 209
Postoperative acute kidney injury in lung transplant recipients 209
Gardening in greenhouses as a risk factor for silicosis 206
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 206
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 206
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 205
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 204
Biomarkers in sarcoidosis: The contribution of system biology 203
Proteomic investigation of pulmonary sarcoidosis 202
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 202
Concentrations of major elements and mercury in unstimulated human saliva 200
IPF mortality in waiting list for lung transplantation 196
Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome 195
Urgent contralateral pneumonectomy after single lung transplantation for lymphangioleiomyomatosis 194
Pollen grain viability in Parietaria judaica L. during the long blooming period and correlation with meteorological conditions and allergic diseases 191
Totale 26.136
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.315
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.315
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.098 0 0 146 219 127 71 122 124 119 291 311 568
2022/20233.957 295 344 489 589 389 774 78 318 394 95 127 65
2023/20242.810 136 59 231 100 102 760 968 71 17 73 52 241
2024/20255.380 147 296 559 289 689 279 159 271 383 260 624 1.424
2025/202613.271 1.053 1.713 1.536 1.499 2.424 551 1.535 369 421 702 320 1.148
2026/20271.571 466 505 600 0 0 0 0 0 0 0 0 0
Totale 44.422